Commentary

Video

Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC

Author(s):

Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.

Robert Wang, MD, a urology fellow at Fox Chase Cancer Center, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing renal cell carcinoma (RCC) from oncocytic renal masses.

During the 2024 American Urological Association Annual Meeting Wang and coauthors presented findings from a retrospective study of 78 patients who underwent 99mTc-sestamibi single-photon emission CT/x-ray CT, a nuclear imaging technique that utilizes a mitochondria-targeting tracer to distinguish RCC from oncocytic renal masses. Study authors found that the use of quantitative hot and cold target-to-background ratio cutoffs of 0.46 and 0.6 improved the negative predictive value of the approach to 89% and 88%, respectively, from a qualitative baseline of 80%. However, the false positive rates for the respective cutoffs were 23.1% and 3.8%, a significant increase from the 1.9% observed with qualitative interpretation by a radiologist.

Wang notes that the findings from this single-center study at Fox Chase should not dampen the general enthusiasm around the use of molecular imaging in RCC. The approach still displays great promise, with the potential to allow patients to avoid unnecessary surgeries by identifying a mass as benign early in the treatment process, Wang says. This benefit will go a long way towards reducing the cost of care for patients and payers, as well as improving patient quality of life by reducing unnecessary pain, suffering, and anxiety for individuals who may not have cancer at all, Wang explains.

Additionally, clinicians must use caution when translating controlled data from a study such as this to everyday use in the clinic, Wang says. The practical use of approaches such as molecular imagining with 99mTc-sestamibi single-photon emission CT/x-ray CT requires nuance from clinicians, and expert radiologists will always play an important role in tailoring the best care for patients, Wang concludes.

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center